• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.可测量残留疾病(MRD)在血液系统恶性肿瘤(以急性白血病为主)造血干细胞移植中的作用。
Int J Mol Sci. 2019 Oct 28;20(21):5362. doi: 10.3390/ijms20215362.
2
Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.急性白血病患者在接受清髓性造血细胞移植前后微小残留病的测量。
Best Pract Res Clin Haematol. 2013 Sep;26(3):279-84. doi: 10.1016/j.beha.2013.10.008. Epub 2013 Oct 16.
3
Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene.异基因造血干细胞移植治疗急性淋巴细胞白血病的微小残留病评估与干预
Expert Rev Anticancer Ther. 2020 Jun;20(6):453-464. doi: 10.1080/14737140.2020.1766973. Epub 2020 May 27.
4
The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.全身照射方案对接受异基因造血干细胞移植的儿童和青年急性淋巴细胞白血病患者结局的影响。
Pediatr Blood Cancer. 2020 Feb;67(2):e28079. doi: 10.1002/pbc.28079. Epub 2019 Nov 14.
5
WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.WT1 可测量残留病检测在接受异基因造血干细胞移植的急性髓系白血病患者中的应用:最佳时间点、阈值和候选者。
Biol Blood Marrow Transplant. 2019 Oct;25(10):1925-1932. doi: 10.1016/j.bbmt.2019.05.033. Epub 2019 Jun 4.
6
[Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].多参数流式细胞术预处理微小残留病监测对异基因造血干细胞移植后急性髓系白血病预后的影响
Zhonghua Xue Ye Xue Za Zhi. 2017 Feb 14;38(2):118-123. doi: 10.3760/cma.j.issn.0253-2727.2017.02.007.
7
Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.异基因造血干细胞移植前可检测到的微小残留病预示急性淋巴细胞白血病患儿预后极差。
Pediatr Blood Cancer. 2007 Jan;48(1):93-100. doi: 10.1002/pbc.20794.
8
Impact of post-transplant minimal residual disease on the clinical outcome of pediatric acute leukemia.移植后微小残留病对小儿急性白血病临床结局的影响。
Pediatr Transplant. 2017 Jun;21(4). doi: 10.1111/petr.12926. Epub 2017 Mar 31.
9
Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.干扰素-α:异基因造血干细胞移植后急性白血病/骨髓增生异常综合征微小残留病的一种潜在有效治疗方法。
Biol Blood Marrow Transplant. 2015 Nov;21(11):1939-47. doi: 10.1016/j.bbmt.2015.06.014. Epub 2015 Jun 23.
10
The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.多参数流式细胞术使用不同于正常的面板检测微小残留病在异基因移植后急性髓系白血病患者中的应用,以预测复发。
Int J Lab Hematol. 2019 Oct;41(5):607-614. doi: 10.1111/ijlh.13070. Epub 2019 Jun 4.

引用本文的文献

1
Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation.移植前流式细胞术、WT1表达和二代测序相结合用于微小残留病监测,在预测接受异基因移植的急性髓系白血病患者的预后方面很有效。
Ann Hematol. 2025 Apr 28. doi: 10.1007/s00277-025-06384-0.
2
Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.缺乏证据支持移植前巩固治疗对接受异基因造血干细胞移植的急性髓系白血病完全缓解2期患者有显著益处。
Cancers (Basel). 2025 Apr 19;17(8):1364. doi: 10.3390/cancers17081364.
3
Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission.全身照射与化疗清髓性预处理用于首次完全缓解的B细胞急性淋巴细胞白血病患者的比较
Sci Rep. 2025 Mar 24;15(1):10079. doi: 10.1038/s41598-025-94556-3.
4
Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogenetics, IKZF1 deletions and minimal residual disease.接受异基因造血干细胞移植和酪氨酸激酶抑制剂治疗的费城染色体阳性成人急性淋巴细胞白血病患者:基于细胞遗传学、IKZF1缺失和微小残留病的临床预测模型的开发与验证
Ann Hematol. 2025 Mar;104(3):1867-1876. doi: 10.1007/s00277-025-06202-7. Epub 2025 Jan 23.
5
Editorial: 50 years of BMT: risk stratification, donor matching and stem cell collection for transplantation.社论:骨髓移植50年:移植的风险分层、供者匹配与干细胞采集
Front Oncol. 2023 Dec 19;13:1321334. doi: 10.3389/fonc.2023.1321334. eCollection 2023.
6
Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies.血液系统恶性肿瘤免疫治疗中的新兴治疗靶点及耐药机制
Cancers (Basel). 2023 Dec 8;15(24):5765. doi: 10.3390/cancers15245765.
7
Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients.急性白血病患者异基因造血干细胞移植前后单核细胞来源的髓系抑制细胞(M-MDSC)的评估
EJHaem. 2023 Sep 21;4(4):1089-1095. doi: 10.1002/jha2.795. eCollection 2023 Nov.
8
MRD-directed and risk-adapted individualized stratified treatment of AML.急性髓系白血病的微小残留病导向及风险适应性个体化分层治疗
Chin J Cancer Res. 2023 Oct 30;35(5):451-469. doi: 10.21147/j.issn.1000-9604.2023.05.04.
9
Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.接受异基因造血干细胞移植的成年急性淋巴细胞白血病患者的免疫表型微小残留病监测
Front Oncol. 2023 Feb 22;13:1047554. doi: 10.3389/fonc.2023.1047554. eCollection 2023.
10
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.HOVON-SAKK132试验中CD34+CD38-急性髓系白血病干细胞频率预后相关性的前瞻性验证
Blood. 2023 May 25;141(21):2657-2661. doi: 10.1182/blood.2022019160.

本文引用的文献

1
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.急性淋巴细胞白血病中的微小残留病:技术与临床进展
Front Oncol. 2019 Aug 7;9:726. doi: 10.3389/fonc.2019.00726. eCollection 2019.
2
MRD in AML: The Role of New Techniques.急性髓系白血病中的微小残留病:新技术的作用
Front Oncol. 2019 Jul 23;9:655. doi: 10.3389/fonc.2019.00655. eCollection 2019.
3
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.GIMEMA AML1310 试验:针对新诊断的急性髓系白血病的年轻成年人,采用风险适应、MRD 导向的治疗。
Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.
4
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia.B 细胞急性淋巴细胞白血病的生物学特性与治疗的最新进展
Blood Lymphat Cancer. 2018 Sep 25;8:47-61. doi: 10.2147/BLCTT.S170351. eCollection 2018.
5
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.采用标准化的下一代免疫球蛋白和 T 细胞受体基因重排测序技术鉴定急性淋巴细胞白血病微小残留病(MRD)标志物:一项 EuroClonality-NGS 验证研究。
Leukemia. 2019 Sep;33(9):2241-2253. doi: 10.1038/s41375-019-0496-7. Epub 2019 Jun 26.
6
WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.WT1 可测量残留病检测在接受异基因造血干细胞移植的急性髓系白血病患者中的应用:最佳时间点、阈值和候选者。
Biol Blood Marrow Transplant. 2019 Oct;25(10):1925-1932. doi: 10.1016/j.bbmt.2019.05.033. Epub 2019 Jun 4.
7
Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in mutant acute myeloid leukemia.分子学微小残留病阴性和干细胞动员潜力降低预示着突变型急性髓系白血病自体移植后预后良好。
Haematologica. 2020 Jan;105(1):e9-e12. doi: 10.3324/haematol.2019.216457. Epub 2019 May 23.
8
The emerging role of measurable residual disease detection in AML in morphologic remission.在形态缓解的 AML 中,可测量残留疾病检测的新兴作用。
Semin Hematol. 2019 Apr;56(2):125-130. doi: 10.1053/j.seminhematol.2018.09.001. Epub 2018 Sep 19.
9
Measurable residual disease testing for personalized treatment of acute myeloid leukemia.用于急性髓系白血病个体化治疗的可测量残留病检测
APMIS. 2019 May;127(5):337-351. doi: 10.1111/apm.12926. Epub 2019 Mar 28.
10
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.实时定量逆转录聚合酶链反应检测 e1a2 BCR-ABL1 指导费城染色体阳性急性淋巴细胞白血病微小残留病的标准化和共识指南。
Leukemia. 2019 Aug;33(8):1910-1922. doi: 10.1038/s41375-019-0413-0. Epub 2019 Mar 11.

可测量残留疾病(MRD)在血液系统恶性肿瘤(以急性白血病为主)造血干细胞移植中的作用。

The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.

机构信息

Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Ludwik Pasteur 4, 50-367 Wroclaw, Poland.

Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Derech Sheba 2, 52-621 Ramat Gan, Israel.

出版信息

Int J Mol Sci. 2019 Oct 28;20(21):5362. doi: 10.3390/ijms20215362.

DOI:10.3390/ijms20215362
PMID:31661875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6862140/
Abstract

The significance of measurable residual disease (MRD) in hematopoietic stem cell transplantation (HSCT) is well recognized in different hematological malignancies, but the evidence indicate that pre-transplant MRD status is of particular importance in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In ALL, inadequate response at the level of MRD is a commonly accepted risk factor for relapse and thus an indication for allogeneic HSCT. Similarly, growing evidence from the literature strongly suggest that MRD detected by multiparameter flow cytometry or molecular techniques should be also used for risk stratification in AML at the time of HSCT. Despite the well-defined association of MRD and outcomes of HSCT in acute leukemias, there are still many open issues such as the role of additional pre-transplant consolidation for MRD eradication, the ability of HSCT to overcome negative influence of MRD positivity on survival, the impact of conditioning regimen intensity on MRD clearance post HSCT, and transplantation outcomes or the selection of optimal donor with regards to MRD status. In addition, the role of MRD assessment in guiding post-transplant maintenance treatment should also be addressed in prospective trials. These open issues mostly awaiting further clinical studies will be discussed in our current review.

摘要

在不同的血液恶性肿瘤中,造血干细胞移植(HSCT)中可测量残留疾病(MRD)的意义已得到广泛认可,但有证据表明,移植前 MRD 状态在急性淋巴细胞白血病(ALL)和急性髓细胞白血病(AML)中尤为重要。在 ALL 中,MRD 水平的不充分反应是复发的常见危险因素,因此也是进行异基因 HSCT 的指征。同样,来自文献的越来越多的证据强烈表明,在 HSCT 时,通过多参数流式细胞术或分子技术检测到的 MRD 也应该用于 AML 的风险分层。尽管 MRD 与 HSCT 在急性白血病中的结果之间存在明确的关联,但仍存在许多悬而未决的问题,例如在消灭 MRD 方面额外的移植前巩固治疗的作用、HSCT 克服 MRD 阳性对生存的负面影响的能力、预处理方案强度对 HSCT 后 MRD 清除的影响、移植结果或根据 MRD 状态选择最佳供体等。此外,MRD 评估在指导移植后维持治疗中的作用也应在前瞻性试验中得到解决。这些悬而未决的问题主要有待进一步的临床研究,我们将在本次综述中进行讨论。